StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$148.36−1.16 (-0.78%)

Close on Nov 2, 2026Market cap $366.03BP/E 118.7Yield 2.21%

Merck Dificid (fidaxomicin by Quarter

Dificid (fidaxomicin — C. difficile infection) — Worldwide sales ($M) ($M)

QuarterlyAnnual

Merck Dificid (fidaxomicin: $22M in Q2 2026, down 77.1% from a year earlier. That is the lowest of the 22 quarters on record here.

Latest, Q2 2026
22
Period ended Jun 30, 2026
Change on a year earlier
-77.1%
96 in Q2 2025
History
22 quarters
Since Q1 2021
Sources
5
Documents cited below

Where the Q2 2026 figure comes from

“|| Dificid | 22 | 96 | -77 | 11 | 83 | -87 | 12 | 13 | -11”

Source: Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗

Reported in Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedDificid (fidaxomicin — C. difficile infection) — Worldwide sales ($M) ($M)Year on yearSource
Q2 2026Jun 30, 202622-77.1%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q1 2026Mar 31, 202634-59.0%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q4 2025Dec 31, 202525-68.4%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q3 2025Sep 30, 202543-55.2%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q2 2025Jun 30, 202596+4.3%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q1 2025Mar 31, 202583+13.7%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q4 2024Dec 31, 202479-9.2%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q3 2024Sep 30, 202496+29.7%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q2 2024Jun 30, 202492+21.1%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q1 2024Mar 31, 202473+12.3%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q4 2023Dec 31, 202387+29.9%Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q3 2023Sep 30, 202374-3.9%Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q2 2023Jun 30, 202376+15.2%Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q1 2023Mar 31, 202365+25.0%Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q4 2022Dec 31, 202267+11.7%Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗
Q3 2022Sep 30, 202277+42.6%Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗

Breakdown

What makes up dificid (fidaxomicin

Cite this data

StockData. (2026). Merck Dificid (fidaxomicin ($M), quarterly Q1 2021–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-dificid

See every metric in the Merck KPI table. Data updated Oct 26, 2026.